26 citations,
May 2012 in “Cellular and Molecular Life Sciences” NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.
[object Object] 224 citations,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” ERG increases SOX9, promoting prostate cancer growth and invasion.
June 2010 in “Journal of Chemical Crystallography” The compound was successfully made and shows potential for treating prostate cancer.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
18 citations,
March 2009 in “Medical Hypotheses” The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.
March 2011 in “European Urology Supplements” Gene variation affects prostate issues and hair loss.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
284 citations,
February 2008 in “Pediatrics” Chemicals and body size might change when puberty starts and progresses, but more research is needed to confirm this.
16 citations,
April 2007 in “Journal of Obstetrics and Gynaecology Research” Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.
7 citations,
October 2017 in “Urologic Oncology: Seminars and Original Investigations” Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.
92 citations,
November 2003 in “The Journals of Gerontology” Testosterone supplements can increase muscle mass and strength in older men with low levels, but long-term effects and risks need more research.
1 citations,
May 2001 in “Pharmacology & Toxicology” Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.
72 citations,
October 1998 in “Baillière's clinical endocrinology and metabolism” Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.
1 citations,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
101 citations,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
9 citations,
July 2018 in “Medicine” Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.
139 citations,
December 2020 in “Cell Stem Cell” Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.
514 citations,
February 2011 in “International journal of women's health” Different treatments for PCOS focus on the specific symptoms, with weight loss and lifestyle changes being important.
3 citations,
January 2001 in “Cambridge University Press eBooks” Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.
June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
1265 citations,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.
9 citations,
September 2009 in “The Prostate” Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.
[object Object]
1 citations,
August 2015 in “Journal of the Korean neurological association” A man had a rare stroke possibly due to taking finasteride, which might have increased his hormone levels causing a blood clot. His memory loss didn't fully recover even after stopping the medication.
1 citations,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
March 2024 in “PLoS medicine” Physical activity, height, and smoking affect prostate cancer risk.
70 citations,
November 2013 in “The BMJ” Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
20 citations,
June 2017 in “Hormone Molecular Biology and Clinical Investigation” Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
16 citations,
January 2010 in “Drug Metabolism and Pharmacokinetics” Finasteride's effect on hair loss and prostate enlargement depends on its binding to an enzyme, with maximum impact at 0.2 mg dose.
January 2003 in “Humana Press eBooks” Dihydrotestosterone and 5α-Reductase play a role in hair loss and prostate health, and finasteride can increase hair growth in men without affecting sperm production, but it doesn't work for postmenopausal women with hair loss.
12 citations,
February 2012 in “New England journal of medicine/The New England journal of medicine” A 72-year-old man had severe fatigue, weight loss, and frequent loose stools.